MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Zai Lab Ltd ADR

Chiusa

SettoreSettore sanitario

33.64 2.69

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

32.72

Massimo

33.94

Metriche Chiave

By Trading Economics

Entrata

7.7M

-41M

Vendite

3.5M

110M

Margine di Profitto

-37.032

Dipendenti

1,869

EBITDA

1.4M

-55M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+59.84% upside

Dividendi

By Dow Jones

Utili prossimi

11 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-439M

3.8B

Apertura precedente

30.95

Chiusura precedente

33.64

Notizie sul Sentiment di mercato

By Acuity

100%

0%

361 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Zai Lab Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

7 ott 2025, 16:58 UTC

Utili

BMW Trims 2025 View, Citing Weaker Performance in China

7 ott 2025, 23:43 UTC

Discorsi di Mercato

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7 ott 2025, 23:36 UTC

Discorsi di Mercato

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7 ott 2025, 23:19 UTC

Discorsi di Mercato

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7 ott 2025, 22:50 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

7 ott 2025, 22:50 UTC

Discorsi di Mercato

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7 ott 2025, 22:40 UTC

Discorsi di Mercato

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7 ott 2025, 21:56 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

7 ott 2025, 21:56 UTC

Discorsi di Mercato

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7 ott 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

7 ott 2025, 20:44 UTC

Azioni calde

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7 ott 2025, 19:42 UTC

Discorsi di Mercato

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7 ott 2025, 19:23 UTC

Acquisizioni, Fusioni, Takeovers

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7 ott 2025, 19:07 UTC

Discorsi di Mercato

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7 ott 2025, 19:02 UTC

Discorsi di Mercato

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7 ott 2025, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

7 ott 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

7 ott 2025, 16:20 UTC

Discorsi di Mercato

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7 ott 2025, 16:15 UTC

Discorsi di Mercato

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7 ott 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

7 ott 2025, 15:37 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

7 ott 2025, 15:37 UTC

Discorsi di Mercato

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7 ott 2025, 15:33 UTC

Discorsi di Mercato

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7 ott 2025, 15:25 UTC

Discorsi di Mercato

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7 ott 2025, 15:15 UTC

Discorsi di Mercato

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7 ott 2025, 15:04 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

7 ott 2025, 15:04 UTC

Discorsi di Mercato

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7 ott 2025, 14:56 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

7 ott 2025, 14:56 UTC

Discorsi di Mercato

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7 ott 2025, 14:52 UTC

Utili

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Confronto tra pari

Modifica del prezzo

Zai Lab Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

59.84% in crescita

Previsioni per 12 mesi

Media 52.57 USD  59.84%

Alto 69 USD

Basso 39 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

7 ratings

6

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

28.13 / 31.12Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bullish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat